News Sentiment

RDHL sentiment intelligence

Redhill Biopharma Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 45 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 0.81 Week of 12 Jun 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-21.4% over one week, -21.4% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Redhill Biopharma Ltd (RDHL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction -21.4% Price reacting lower
Trend fit Trend inactive -21.4% over four weeks
Fair value -90.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 25
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
TradingKey 7
PR Newswire 6
Investing.com 3
GuruFocus 2
Sahm 2
grafa.com 2
Investing.com Canada 1

Event Lens

What the news is about

Classified themes
Market update 29
Regulatory and legal 6
Earnings 4
Deals and strategy 4
Analyst action 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 45
TradingKey Direct company coverage

Redhill Biopharma Ltd (RDHL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a company overview for Redhill Biopharma Ltd (RDHL) focusing on revenue breakdown. However, it explicitly states that relevant data regarding business segments and regional revenue have not been disclosed by the company yet. The page displays current stock i

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 21:40
Source
TradingKey
TradingKey Direct company coverage

Redhill Biopharma Ltd (RDHL) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Redhill Biopharma Ltd's (RDHL) dividend and stock split history. It notes that the company has distributed no dividends over the past five years and lists several merger-related stock splits, including 25-to-1 splits scheduled for August 6, 20

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 21:40
Source
TradingKey
Investing.com Direct company coverage

RedHill Biopharma raises $6M in private placement

RedHill Biopharma Ltd. announced it has entered into a definitive agreement for a private placement expected to generate $6 million in gross proceeds. The company will sell 8,571,429 American Depositary Shares at $0.70 per ADS with accompanying warrants. The proceeds are intended

Tone
Positive 71/100
Event
Market update
Published
18 Jun 2026 12:40
Source
Investing.com
Investing.com Canada Direct company coverage

RedHill Biopharma raises $6M in private placement By Investing.com

RedHill Biopharma announced a definitive agreement for a private placement expected to generate $6 million in gross proceeds. The company will sell 8,571,429 American Depositary Shares at $0.70 per ADS, with accompanying warrants that could bring in an additional $13.4 million if

Tone
Positive 66/100
Event
Market update
Published
18 Jun 2026 12:39
Source
Investing.com Canada
PR Newswire Direct company coverage

RedHill Biopharma Announces Up To $19.4 Million Private Placement

RedHill Biopharma announced a private placement totaling up to $19.4 million, comprising $6 million upfront from the sale of American Depositary Shares (ADSs) and accompanying warrants, with an additional potential $13.4 million from the full exercise of these warrants. The funds

Tone
Positive 63/100
Event
Market update
Published
18 Jun 2026 11:39
Source
PR Newswire
TradingKey Direct company coverage

Redhill Biopharma Ltd (RDHL) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast analysis for Redhill Biopharma Ltd (RDHL), noting that no specific earnings forecast score is currently available, contrasting with the pharmaceuticals industry average of 7.84. It highlights the company's current stock performance, mark

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 23:39
Source
TradingKey
TradingKey Direct company coverage

Redhill Biopharma Ltd (RDHL) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Redhill Biopharma Ltd (RDHL), detailing its current price momentum, support and resistance levels, and insights from various technical indicators and moving averages. As of June 17, 2026, the stock has a price momentum score of 2.32,

Tone
Negative 41/100
Event
Market update
Published
17 Jun 2026 23:39
Source
TradingKey
Sahm Direct company coverage

RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo

RedHill Biopharma Ltd. announced it has started recognition and enforcement proceedings in Korea for an $10.9 million New York Supreme Court judgment against Kukbo Co. Ltd. The judgment, which became final in November 2025 for the principal award, and in March 2026 for legal fees

Tone
Positive 65/100
Event
Market update
Published
11 Jun 2026 23:39
Source
Sahm
Stock Titan Direct company coverage

FDA grants rare pediatric disease status to RedHill (RDHL) drug opaganib

RedHill Biopharma announced that its investigational drug opaganib received rare pediatric disease designation from the FDA for treating neuroblastoma, a cancer affecting children. This designation, in addition to existing orphan drug status, makes opaganib eligible for benefits

Tone
Positive 70/100
Event
Regulatory and legal
Published
10 Jun 2026 09:09
Source
Stock Titan
Your Wyoming Link Direct company coverage

RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation

RedHill Biopharma announced that its drug opaganib has received Rare Pediatric Disease (RPD) designation from the FDA for the treatment of neuroblastoma, a type of cancer affecting babies and young children. This designation, in addition to its existing Orphan Drug designation, o

Tone
Positive 74/100
Event
Market update
Published
10 Jun 2026 08:40
Source
Your Wyoming Link
grafa.com Direct company coverage

RedHill Biopharma opaganib wins FDA rare pediatric disease status

RedHill Biopharma received Rare Pediatric Disease designation from the FDA for its drug opaganib, intended to treat neuroblastoma, a childhood cancer. This designation, alongside an existing orphan drug status, makes the company eligible for a Priority Review Voucher upon approva

Tone
Positive 74/100
Event
Market update
Published
09 Jun 2026 12:05
Source
grafa.com
Stock Titan Direct company coverage

RedHill Biopharma (Nasdaq: RDHL) enforces $10.9M final judgment against Kukbo

RedHill Biopharma (Nasdaq: RDHL) has initiated legal proceedings in Korea to enforce a $10.9 million New York Supreme Court judgment against Kukbo Co. Ltd. This judgment includes a main award of $8.9 million and $1.95 million for legal fees, both accruing 9% statutory interest an

Tone
Neutral 50/100
Event
Market update
Published
08 Jun 2026 20:40
Source
Stock Titan
Investing.com Direct company coverage

RedHill Biopharma begins Korea enforcement of $10.9M judgment

RedHill Biopharma has initiated proceedings in Korea to enforce a New York Supreme Court judgment against Kukbo Co. Ltd for approximately $10.9 million. The judgment, which includes principal, legal fees, and accrued interest, became eligible for enforcement after Kukbo failed to

Tone
Positive 65/100
Event
Market update
Published
08 Jun 2026 20:10
Source
Investing.com
grafa.com Direct company coverage

RedHill Biopharma commences enforcement of $10.9M judgment against Kukbo

RedHill Biopharma has initiated enforcement proceedings in South Korea to collect a $10.9 million judgment against Kukbo. This judgment, which includes an $8.9 million principal and $1.95 million in legal fees with 9% interest, stems from a breach of contract dispute. The New Yor

Tone
Positive 73/100
Event
Deals and strategy
Published
08 Jun 2026 15:10
Source
grafa.com
Investing.com South Africa Direct company coverage

RedHill Biopharma begins Korea enforcement of $10.9M judgment By Investing.com

RedHill Biopharma has initiated recognition and enforcement proceedings in Korea for a New York Supreme Court judgment against Kukbo Co. Ltd, totaling approximately $10.9 million. The judgment includes $8.9 million in principal and $1.95 million in legal fees and expenses, with a

Tone
Positive 71/100
Event
Market update
Published
08 Jun 2026 11:10
Source
Investing.com South Africa
EQS News Direct company coverage

RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak | Corporate

RedHill Biopharma is actively pursuing collaborations, including with the WHO, to advance its investigational oral drug opaganib for an emerging Ebola virus disease (EVD) outbreak. Opaganib, which has demonstrated antiviral activity in severe COVID-19 and preclinical EVD studies,

Tone
Positive 71/100
Event
Regulatory and legal
Published
03 Jun 2026 20:40
Source
EQS News
AD HOC NEWS Direct company coverage

RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak

RedHill Biopharma is actively pursuing collaborations to advance its investigational oral drug, opaganib, for the treatment of Ebola Virus Disease (EVD), particularly in response to the Bundibugyo ebolavirus outbreak which lacks approved treatments. The company is in discussions

Tone
Positive 73/100
Event
Regulatory and legal
Published
03 Jun 2026 16:10
Source
AD HOC NEWS
Stock Titan Direct company coverage

Experimental Ebola pill opaganib in WHO CORE trial talks

RedHill Biopharma is actively seeking collaborations, including with the WHO SOLIDARITY CORE platform, to evaluate its investigational drug opaganib as a potential treatment for the Bundibugyo ebolavirus subtype. The company highlights opaganib's Phase 3 severe COVID-19 data show

Tone
Neutral 50/100
Event
Regulatory and legal
Published
03 Jun 2026 05:39
Source
Stock Titan
Stock Titan Direct company coverage

RedHill Biopharma (RDHL) pursues collaborations to test opaganib in Ebola

RedHill Biopharma is actively seeking collaborations to advance its investigational oral drug, opaganib, for treating Ebola virus disease, especially given the current outbreak of the rare Bundibugyo ebolavirus sub-type. The company is in discussions with the World Health Organiz

Tone
Positive 64/100
Event
Regulatory and legal
Published
03 Jun 2026 05:39
Source
Stock Titan
Sahm Direct company coverage

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

RedHill Biopharma is actively discussing the clinical advancement of its investigational oral drug, opaganib, for Ebola virus disease (EVD), especially given a rapidly evolving outbreak of the rare Bundibugyo ebolavirus sub-type for which no approved medications exist. Opaganib a

Tone
Positive 71/100
Event
Regulatory and legal
Published
02 Jun 2026 19:10
Source
Sahm